Form 4: Sangamo Exec Sells Shares for Tax Withholding

A Sangamo Therapeutics executive disposed of 36,676 shares of common stock for mandatory tax withholding purposes following an RSU vesting event.

Summary

• Nathalie Dubois-Stringfellow, SVP-Chief Development Officer of Sangamo Therapeutics, Inc. (SGMO), reported a disposition of 36,676 shares of common stock.
• The transaction occurred on January 22, 2026, at a price of $0.3985 per share.
• The disposition was solely for mandatory tax withholding purposes related to the vesting of a Restricted Stock Unit (RSU) grant and does not represent a discretionary trade.
• Following this transaction, Dubois-Stringfellow beneficially owns 693,128 shares of Sangamo Therapeutics common stock.
• The beneficial ownership includes 52,387 shares from a January 22, 2026 RSU vesting installment, 5,010 shares from a February 24, 2023 RSU grant with ongoing quarterly vesting, and 120,000 shares from a February 25, 2025 RSU grant with future vesting installments.
• Beneficial ownership also includes 5,000 shares acquired on May 30, 2025, and 5,000 shares acquired on November 28, 2025, under the company's 2020 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction related to executive compensation and tax withholding. It does not indicate any change in company fundamentals or management's outlook, thus maintaining a neutral sentiment.

Positives

• The vesting of Restricted Stock Units indicates continued executive compensation and alignment of interests with shareholders.
• Acquisitions through the Employee Stock Purchase Plan demonstrate the executive's ongoing investment in the company.

Negatives

• The disposition of 36,676 shares, even for tax purposes, reduces the executive's direct share ownership.

Future Outlook

Future vesting installments are scheduled for the reporting person's RSU grants, including quarterly installments through February 24, 2026, for the 2023 grant, and a significant portion vesting on February 25, 2026, with subsequent quarterly installments for the 2025 grant.

Management Comments

• The disposition of shares was solely for mandatory tax withholding purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

Industry Context

This Form 4 filing details a routine insider transaction common across all publicly traded companies, particularly those that utilize equity compensation such as Restricted Stock Units (RSUs) for their executives. In the biotechnology sector, where long-term development cycles are common, RSUs are a standard component of executive compensation packages designed to align management incentives with long-term shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a widely adopted practice across various industries, including biotechnology, aligning with global benchmarks for executive incentive structures.
• The disposition of shares for mandatory tax withholding upon RSU vesting is a standard, non-discretionary event, consistent with compensation practices observed in comparable companies like Biogen (BIIB) or Gilead Sciences (GILD) when their executives' equity awards vest.

Related Party Transactions

• The reporting person's Restricted Stock Unit (RSU) grants from January 22, 2024, February 24, 2023, and February 25, 2025, represent equity compensation from the issuer.
• Acquisitions of shares on May 30, 2025, and November 28, 2025, under the Issuer's 2020 Employee Stock Purchase Plan (ESPP) are also transactions between the executive and the company.

Stakeholder Impact

• Shareholders: A minor, routine reduction in an executive's direct ownership due to tax obligations, which is a common occurrence and generally not indicative of a change in confidence.
• Employees: The transaction reflects standard executive compensation practices, which can be a positive signal for employee incentive programs.

Next Steps

• Continued vesting of the Reporting Person's RSU grants according to their respective schedules, with the next significant vesting events expected on February 24, 2026, and February 25, 2026.

Key Dates

Recommendation

The filing details a routine disposition of shares by an executive for mandatory tax withholding following RSU vesting. This is a non-discretionary event and does not reflect a change in management's outlook or a strategic move, thus providing no new fundamental information to alter an investment thesis. Investors should maintain their current position based on broader company fundamentals.

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, RSU, Tax Withholding, Stock Sale, Biotechnology